Wendy De Roock

6.0k total citations · 2 hit papers
31 papers, 2.8k citations indexed

About

Wendy De Roock is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Wendy De Roock has authored 31 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Wendy De Roock's work include Colorectal Cancer Treatments and Studies (28 papers), Lung Cancer Treatments and Mutations (15 papers) and Gastric Cancer Management and Outcomes (8 papers). Wendy De Roock is often cited by papers focused on Colorectal Cancer Treatments and Studies (28 papers), Lung Cancer Treatments and Mutations (15 papers) and Gastric Cancer Management and Outcomes (8 papers). Wendy De Roock collaborates with scholars based in Belgium, United States and Germany. Wendy De Roock's co-authors include Sabine Tejpar, Eric Van Cutsem, Hubert Piessevaux, Bart Biesmans, Veerle de Vriendt, Fortunato Ciardiello, Nicola Normanno, Marc Peeters, Yves Humblet and Gert De Hertogh and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Wendy De Roock

31 papers receiving 2.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

2007 660 citations Wendy De Roock, Hubert Piessevaux et al. Annals of Oncology profile →
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

2010 573 citations Wendy De Roock, Derek J. Jonker et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wendy De Roock Belgium	16	2.3k	1.1k	963	657	560	31	2.8k
Dennis Salonga United States	24	2.1k 0.9×	1.2k 1.1×	630 0.7×	1.4k 2.2×	546 1.0×	33	3.4k
David J. Mauro United States	11	1.6k 0.7×	755 0.7×	451 0.5×	459 0.7×	376 0.7×	26	2.0k
Bart Biesmans Belgium	11	2.1k 0.9×	861 0.8×	1.1k 1.2×	471 0.7×	478 0.9×	20	2.5k
Sid Suggs United States	8	2.1k 0.9×	830 0.7×	868 0.9×	646 1.0×	634 1.1×	8	2.8k
Sara De Dosso Switzerland	21	3.0k 1.3×	1.1k 1.0×	1.1k 1.2×	806 1.2×	777 1.4×	57	3.6k
Katia Bencardino Italy	24	1.8k 0.8×	806 0.7×	669 0.7×	592 0.9×	591 1.1×	77	2.4k
Silvia Benvenuti Italy	20	1.6k 0.7×	923 0.8×	586 0.6×	969 1.5×	436 0.8×	40	2.6k
Carlotta Antoniotti Italy	19	2.3k 1.0×	819 0.7×	932 1.0×	432 0.7×	483 0.9×	109	2.6k
Pu Yan Switzerland	23	1.3k 0.6×	368 0.3×	955 1.0×	815 1.2×	526 0.9×	34	2.3k
Cristiana Lupi Italy	18	1.7k 0.7×	631 0.6×	608 0.6×	708 1.1×	370 0.7×	35	2.8k

Countries citing papers authored by Wendy De Roock

Since Specialization

Citations

This map shows the geographic impact of Wendy De Roock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy De Roock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy De Roock more than expected).

Fields of papers citing papers by Wendy De Roock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy De Roock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy De Roock. The network helps show where Wendy De Roock may publish in the future.

Co-authorship network of co-authors of Wendy De Roock

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy De Roock. A scholar is included among the top collaborators of Wendy De Roock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy De Roock. Wendy De Roock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rasschaert, Marika, Randal D’hondt, Christof Vulsteke, et al.. (2024). Malnutrition prevalence in cancer patients in Belgium: The ONCOCARE study. Supportive Care in Cancer. 32(2). 135–135. 9 indexed citations

Saridaki, Zenia, Joanne B. Weidhaas, Heinz‐Josef Lenz, et al.. (2014). A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy. Clinical Cancer Research. 20(17). 4499–4510. 52 indexed citations

Vriendt, Veerle de, Wendy De Roock, Antonio Fabio Di Narzo, et al.. (2013). DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype. Biomarkers. 18(6). 516–524. 19 indexed citations

Strimpakos, Alexios S, George Pentheroudakis, Vassiliki Kotoula, et al.. (2013). The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab. Clinical Colorectal Cancer. 12(4). 267–274.e2. 25 indexed citations

Roock, Wendy De, Veerle de Vriendt, Nicola Normanno, Fortunato Ciardiello, & Sabine Tejpar. (2010). KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. The Lancet Oncology. 12(6). 594–603. 463 indexed citations

Roock, Wendy De, Derek J. Jonker, Federica Di Nicolantonio, et al.. (2010). Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA. 304(16). 1812–1812. 573 indexed citations breakdown →

Prenen, Hans, Jef De Schutter, Bart Jacobs, et al.. (2009). PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer. Clinical Cancer Research. 15(9). 3184–3188. 241 indexed citations

Prenen, Hans, Bart Jacobs, Wendy De Roock, et al.. (2009). Use of amphiregulin and epiregulin mRNA expression in primary tumors to predict outcome in metastatic colorectal cancer treated with cetuximab. Journal of Clinical Oncology. 27(15_suppl). 4019–4019. 10 indexed citations

Piessevaux, Hubert, Marc Buyse, Wendy De Roock, et al.. (2009). Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Annals of Oncology. 20(8). 1375–1382. 63 indexed citations

10.

Roock, Wendy De, Jef De Schutter, Hans Prenen, et al.. (2009). PIK3CA mutations do not confer resistance to the EGFR-inhibitor cetuximab in chemorefractory metastatic colorectal cancer. 1 indexed citations

11.

Roock, Wendy De, Bart Biesmans, Jef De Schutter, & Sabine Tejpar. (2009). Clinical Biomarkers in Oncology. Molecular Diagnosis & Therapy. 13(2). 103–114. 33 indexed citations

12.

Roock, Wendy De, M. Janssens, Bart Biesmans, et al.. (2009). DUSPs as markers of MEK/Erk activation in primary colorectal cancer. Journal of Clinical Oncology. 27(15_suppl). 4064–4064. 5 indexed citations

13.

Personeni, Nicola, Steffen Fieuws, Hubert Piessevaux, et al.. (2008). Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study. Clinical Cancer Research. 14(18). 5869–5876. 129 indexed citations

14.

Tejpar, Sabine, Wendy De Roock, Bart Biesmans, et al.. (2008). Correlation of high amphiregulin and epiregulin expression in KRAS wild type colorectal primaries with response and survival benefit after treatment with cetuximab and irinotecan for metastatic disease.. Ghent University Academic Bibliography (Ghent University). 9 indexed citations

15.

Fiore, Francesco, Eric Van Cutsem, Pierre Laurent‐Puig, et al.. (2008). Role of Kras mutations in predicting response and survival in irinotecan-refiractory patients treated with cetuximab and irinotecan for metastatic colorectal cancer: Analysis of 281 patients with individual data. Annals of Oncology. 19. 14–14. 5 indexed citations

16.

Tejpar, Sabine, Marc Peeters, Yves Humblet, et al.. (2008). The EVEREST study: relationship between efficacy and K-RAS mutation status in patients with irinotecan-refactory MCRC treated with irinotecan and standard or escalating doses of cetuximab. Ghent University Academic Bibliography (Ghent University). 4 indexed citations

17.

Roock, Wendy De, M. Janssens, Bart Biesmans, et al.. (2008). 98 POSTER DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease. European Journal of Cancer Supplements. 6(12). 33–33. 3 indexed citations

18.

Roock, Wendy De, et al.. (2007). Treatment of Zenker’s diverticulum through a flexible endoscope with a transparent oblique-end hood attached to the tip and a monopolar forceps. Endoscopy. 39(2). 137–140. 58 indexed citations

19.

Roock, Wendy De, Hubert Piessevaux, Joris De Schutter, et al.. (2007). KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Annals of Oncology. 19(3). 508–515. 660 indexed citations breakdown →

20.

Personeni, Nicola, Stephan Störkel, Maria Dêbiec‐Rychter, et al.. (2007). Outcome prediction to cetuximab in advanced colorectal cancer: Analysis of EGFR and HER2 gene copy number by fluorescence in situ hybridization. Journal of Clinical Oncology. 25(18_suppl). 10569–10569. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact